Neuros Medical Secures USD 56 Million Series D to Combat Post-Amputation Pain

EQT Life Sciences has announced a USD 56 million Series D financing round for Neuros Medical, a U.S.-based medical device company that has developed the FDA-approved Altius Direct Electrical Nerve Stimulation System. This funding will enable Neuros Medical to commercialize its device across the U.S. to treat chronic post-amputation pain, a condition affecting up to 80% of amputees with limited non-opioid treatment options. EQT's investment, through the LSP 7 fund and EQT Health Economics strategy, supports Neuros Medical’s mission to provide a non-opioid alternative for managing this underserved medical need. David Veino, CEO of Neuros Medical, emphasizes the significance of this funding to help expand operations and improve life quality for amputees. The Altius system, comprising a nerve cuff electrode and an implantable pulse generator, offers a patient-controlled, on-demand therapy, making it the sole FDA-approved solution in this space. Planting its roots in Aliso Viejo, CA, Neuros Medical is poised to leverage this investment to penetrate a rapidly expanding market and attract further attention to chronic pain management innovations.